HOME
ABOUT US
ADVERTISE
SUBSCRIBE
SITE MAP
HELP
CONTACT
WORK FOR US
Tuesday
7 September 2010
Make BTN my HomePage
NEW RESEARCH STORIES
[ 1015 Results - Showing Results 1 to 30 ]
Pipeline Progress: QRxPharma, Tyrian, Prana and more
(Monday, 6 September 2010)
AS Pharmaxis’s recent “failed” clinical trial can attest, comparing results from two dosings of the same therapeutic carries the risk that an effective treatment can still miss endpoints.
Full Story...
Pam-beating rat whisperer makes debut
(Tuesday, 31 August 2010)
DRUG discoverer Bionomics has found its anti-anxiety and anti-depressant compound BNC210 reduced anxiety in rats without sedating them, as diazepam did.
Full Story...
Clinuvel seeks thriller re-pigmentation
(Friday, 27 August 2010)
LATE-stage drug developer Clinuvel Pharmaceuticals will evaluate a sixth indication for its orphan drug Scenesse in patients with vitiligo, a skin pigmentation disorder which reportedly affected the late Michael Jackson.
Full Story...
Bio Briefs: GTG, Starpharma, OMI and more
(Thursday, 26 August 2010)
GENETIC Technologies has settled two more disputes with US biotechnology companies.
Full Story...
Immuron delivers tasty NASH
(Tuesday, 24 August 2010)
FOLLOWING a successful Phase 1/2 trial of its dairy-derived colostrum powder in patients with metabolic condition fatty liver disease, immunotherapy product developer Immuron must choose whether to tackle insulin resistance, high blood fats or both as it advances its platform to US Food and Drug Administration-compliant trials.
Full Story...
Europe trials reconfirm Sirtex strength
(Thursday, 19 August 2010)
ONCOLOGY treatment company Sirtex Medical says two independent studies in Europe have established that targeted treatment with its microspheres is an effective option for those with inoperable liver cancer.
Full Story...
Virax falls on HIV result
(Tuesday, 17 August 2010)
VIRAX has lost some 60% of its market capitalisation after investors punished it for the poor result from its HIV vaccine trial, which failed to elicit an immune response and missed primary and secondary endpoints.
Full Story...
QRxPharma puts best hip forward
(Tuesday, 10 August 2010)
COMBINATION opioid developer QRxPharma has reported positive results from a 40-patient proof-of-concept study conducted in Germany, which showed better pain relief from an intravenous MoxDuo morphine-oxycodone combination than morphine alone for patients who are experiencing moderate to severe pain after hip-replacement surgery.
Full Story...
Actinogen makes discovery
(Tuesday, 3 August 2010)
PERTH-based company Actinogen says it has discovered a new method to produce anacardic acid, a product that retails for close to $1000 a gram from fine chemical suppliers.
Full Story...
Bionomics adds BNC210 to dessert menu
(Tuesday, 22 June 2010)
ADELAIDE-based drug developer Bionomics has added a second successful Phase 1 study to the clinical armour of its anti-anxiety compound BNC210, reconfirming its safety and observing a 410% or more increase in exposure to the drug when taken after food.
Full Story...
Benitec garners attention of peers
(Thursday, 17 June 2010)
AS Benitec chief scientific officer Peter French settles into his new role as chief executive, the company’s research has been featured in two major science journals.
Full Story...
Bio Briefs: ARCs, CogState, BioProspect and more
(Tuesday, 15 June 2010)
THE Australian Research Collaboration Service has launched a new Compute Cloud service for researchers at publicly funded institutions which allows for large-scale data crunching with high-performance computers.
Full Story...
SIR-Spheres+chemo impresses in Asia
(Thursday, 10 June 2010)
AN independent Phase 2 study of Sirtex’s radioactive microspheres combined with chemotherapy in patients with inoperable liver cancer has shown extended survival by three to four months and a significant reduction in tumour size in 35.5% of patients.
Full Story...
ChemGenex steady on safety
(Tuesday, 8 June 2010)
THERAPEUTICS developer ChemGenex has released safety data from two chronic myeloid leukaemia studies, following Novartis’s news that its second-generation CML treatment is superior to its soon-to-expire product imatinib mesylate.
Full Story...
Bionomics achieves on-target VDA first
(Tuesday, 8 June 2010)
DRUG developer Bionomics has released positive safety data from a Phase 1 study of its lead cancer compound. Speaking to
BTN
from the US, chief executive and managing director Dr Deborah Rathjen called the trial important and said it was the first time a vascular disruptive agent had shown on-target activity that correlated with reduction of that target in patients.
Full Story...
ECG for the mind impresses
(Tuesday, 1 June 2010)
SURGEON and Winthrop Professor Fiona Wood has labelled Neural Diagnostics’ EVestG technology for diagnosing mental health conditions as “leading the world” in a program to air tomorrow night on the ABC.
Full Story...
Immuron working towards HIV microbicide
(Thursday, 27 May 2010)
ORAL immunotherapy product developer Immuron says its dairy-derived polyclonal antibodies product neutralises HIV transmission in artificial environments, and it is waiting on full results from University of Melbourne research before moving into human clinical trials.
Full Story...
Patrys initiates melanoma trial
(Tuesday, 25 May 2010)
HUMAN antibody cancer therapeutics developer Patrys has applied for ethics approval for a Phase 1 study of its lead treatment in a dozen patients to be conducted in Australia.
Full Story...
Genera to collaborate on HPV detection
(Tuesday, 25 May 2010)
MOLECULAR diagnostics manufacturer Genera Biosystems has signed a major collaboration agreement with a top 10 global diagnostic equipment and test manufacturer.
Full Story...
Bio Briefs: Immuron, BioProspect, Eastland and more
(Friday, 21 May 2010)
AUSTRALIA and Israel-based Immuron has announced it intends to collaborate with unlisted pharmaceutical company Nycomed to develop an influenza prevention product.
Full Story...
Mesoblast tackles long-term pain in the neck
(Thursday, 20 May 2010)
BIOLOGIC products developer Mesoblast has received US Food and Drug Administration approval to conduct a Phase 2 study to compare its off-the-shelf stem cell product NeoFuse with a standard-of-care treatment to fuse spinal vertebrae in the neck.
Full Story...
Pharmaxis exhales positive result *UPDATED*
(Tuesday, 18 May 2010)
CYSTIC fibrosis patients treated with Pharmaxis’s inhaled mannitol product during the first of two Phase 3 studies experienced a 7.9% improvement to lung function after 18 months.
Full Story...
Nanopatch more effective than needles
(Thursday, 22 April 2010)
RESEARCHERS in Queensland have demonstrated that a vaccine delivered by a Nanopatch induces a similarly protective immune response as a vaccine delivered by needle and syringe, but uses 100 times less vaccine.
Full Story...
VGX-100 shown to inhibit tumour growth
(Thursday, 15 April 2010)
CIRCADIAN Technologies says it has released data demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth in a variety of animal models of human cancer.
Full Story...
ICGC releases cancer data
(Thursday, 15 April 2010)
THE International Cancer Genome Consortium has released the first data from its study of more than 25,000 cancer genomes and made it freely available on the internet.
Full Story...
BioGrid CART-wheels for cancer patients
(Thursday, 15 April 2010)
DATA-sharing not-for-profit BioGrid Australia has launched a rare cancer register designed to match patients with clinical studies and improve understanding of rare tumours or rare subtypes of common tumours.
BTN
spoke to principal investigator
Dr Clare Scott
about how life science companies can become involved.
Full Story...
KarmelSonix marks the cough
(Monday, 12 April 2010)
DISTRIBUTORS of KarmelSonix’s novel wheeze and cough measurement device WHolter are poised for first sales in Europe after the device received European CE marking – an endorsement its management hopes will lead to regulatory approvals in Australia and the Asia-Pacific region. Managing director
Paul Eisen
spoke to
BTN
.
Full Story...
Hunter chasing funds for COPD therapeutic *UPDATED*
(Thursday, 1 April 2010)
PRIVATE drug developer Hunter Immunology – which is headed up by Medica Australia founder and former Cytopia chief executive Kevin Healey – has revealed its fundraising plans for an upcoming Phase 2b trial of its immune-booster for chronic obstructive pulmonary disease sufferers plagued by acute bronchitis.
Full Story...
Immuron battles insulin resistance in Jerusalem
(Tuesday, 30 March 2010)
IMMURON and Hadassah Hebrew University Medical Center have begun recruiting adult patients with metabolic syndrome and non-alcoholic steatohepatitis for a Phase 1/2 study which will test the immunotherapy product for safety and efficacy, and a reduction in insulin resistance.
Full Story...
Bio Briefs: Atcor, Safety Medical, BioProspect and more
(Tuesday, 30 March 2010)
ATCOR Medical has signed a $US955,000 contract with a major international pharmaceutical company, and existing customer, to supply SphygmoCor systems and clinical trials support services.
Full Story...
Prev
Next
Company Search
Story Search
Advanced Search
UPCOMING
EVENTS
ABIC 2010 - Bridging Biology and Business
14th International Biotechnology Symposium & Exhibition 2010
BIO India Partnering Conference 2010
OZBIO2010
2010 Livestock Biotech Summit
BioPartnering Europe
View all events
TODAY'S NEWS
Broadvector prepares $24.5M bang
Bio People: Australia, Research Australia, KarmelSonix and more *UPDATED*
In Silico: Is the IPO window cracking open?
Capital Briefs: Select, Helicon, PharmaNet and more
Avexa-Calzada rebuffed or engaged?
Bio Briefs: Genesis, Epichem, Sirtex and more
HealthLinx breaches rule *UPDATED*
Pipeline Progress: QRxPharma, Tyrian, Prana and more
Market Pulse: Gaining amid uncertainty
Avexa bioadvisors on board
Disclaimer
|
© Copyright Aspermont Ltd
|
Privacy Policy
|
Terms and Conditions
